Valeo Pharma Inc. (VPHIF)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Jan 2, 2026
Valeo Pharma Revenue
Valeo Pharma had revenue of 12.60M CAD in the quarter ending July 31, 2024, a decrease of -10.52%. This brings the company's revenue in the last twelve months to 53.38M, down -0.16% year-over-year. In the fiscal year ending October 31, 2023, Valeo Pharma had annual revenue of 53.91M with 94.31% growth.
Revenue (ttm)
53.38M CAD
Revenue Growth
-0.16%
P/S Ratio
0.00
Revenue / Employee
485.25K CAD
Employees
110
Market Cap
9.87K USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2023 | 53.91M | 26.17M | 94.31% |
| Oct 31, 2022 | 27.75M | 14.19M | 104.65% |
| Oct 31, 2021 | 13.56M | 6.09M | 81.49% |
| Oct 31, 2020 | 7.47M | 893.00K | 13.58% |
| Oct 31, 2019 | 6.58M | 2.20M | 50.09% |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aida Pharmaceuticals | 40.51M |
| GSRX Industries | 10.13M |
| Bloomios | 8.23M |
| SES Solar | 5.51M |
| Evergreen Sustainable Enterprises | 2.60M |
| Winston Pharmaceuticals | 1.37M |
| FutureWorld | 251.68K |
| CaliPharms | 112.47K |
Valeo Pharma News
- 3 years ago - VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) - PRNewsWire
- 4 years ago - VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK - PRNewsWire
- 4 years ago - VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION - PRNewsWire
- 4 years ago - Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec - GlobeNewsWire
- 4 years ago - Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec - GlobeNewsWire
- 4 years ago - Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta - PRNewsWire
- 4 years ago - /C O R R E C T I O N from Source -- Valeo Pharma inc./ - PRNewsWire
- 4 years ago - Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada - PRNewsWire